Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy
This is a single-arm, non-randomized trial of oxaliplatin and capecitabine. Patients that
are placed on other studies that utilize the same chemotherapy regimen can enter this study.
Those patients will be treated according to the clinical study on which they have been
entered. For patients not on another clinical trial, the treatment outlined below should be
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen
The cycle length is 3 weeks, consisting of 2 weeks of capecitabine treatment followed by 1 week without treatment.
Ian Rabinowitz, MD
University of New Mexico
United States: Institutional Review Board
|University of New Mexico Cancer Center||Albuquerque, New Mexico 87131-5636|
|Hematology Oncology Associates||Albuquerque, New Mexico 87106|
|Lovelace Sandia Health Systems Dept of Hematology||Albuquerque, New Mexico 87108|
|New Mexico Veterans Administration Health Care System||Albuquerque, New Mexico|